KORU Medical Systems is poised for growth with solid revenue increases and multiple growth drivers. Find out why KRMD stock ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...

In this article, we will look at the 10 High Growth NASDAQ Stocks That ... which is used to treat hemolysis in adults with paroxysmal nocturnal hemoglobinuria. Based on the strong pipeline and ...

These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance.

The "Cryotherapy Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The ...

Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Machine learning models can identify undiagnosed PNH cases by analyzing EHR data, potentially transforming rare disease diagnostics. PNH symptoms overlap with other conditions, leading to frequent ...

Thank you for standing by, and welcome to the appellate Pharmaceuticals Third Quarter 2024 earnings conference call. At this time, all participants are in a listen only mode. After the speakers' ...